Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
Study Details
Study Description
Brief Summary
This is multicenter clinical trial to evaluate efficacy and safety of Baricitinib in treatment for COVID-19. This trial will compare Baricitinib, a drug recommended for Rheumatoid Arthritis, against standard of care, to assess its relative effectiveness against COVID-19. By enrolling patients in multiple centers, this trial aims to recruit more patients to evaluate whether this drug slow disease progression or improve survival. Currently no effective therapeutics treatment or vaccine is available in the world for this highly transmissible respiratory borne infection, Covid-19. A number of drug trials are ongoing to measure the efficacy of the drug against the virus. Bangladesh as a resource limited country with limitation to provided health care services to the huge number of Covid-19 patients who will need hospitalization will be benefited from this study. There is no physical, psychological, social, legal risk in this study. The trial therapeutic will be approved form the Directorate of drug Administration (DGDA), Bangladesh.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Baricitinib Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14 |
Drug: Baricitinib
Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
Other Names:
|
| Placebo Comparator: Placebo Continued SOC according as mentioned in operational definition in the protocol |
Drug: Placebo
Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Clinical status assessed by a 7-point ordinal scale on Day 14 [Day 1 to Day 14]
The ordinal scale is an assessment of the clinical status at a given study day. Each day, the worst(ie, lowest ordinal) score from the previous day will be recorded, ie, on Day 3, the lowest ordinal score from Day 2 is obtained and recorded for Day 2. The scale is as follows: Death Hospitalized, on invasive mechanical ventilation or ECMO Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, requiring low flow supplemental oxygen Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol Baricitinib administration) Not hospitalized
Secondary Outcome Measures
- The proportion of participants with treatment emergent adverse events [Day 1 to Day 28]
Other Outcome Measures
- Time to clinical improvement (days): clinical improvement is defined as a ≥ 2-point improvement in clinical status (7-point ordinal scale) from Day 1 [Day 1 to Day 28]
- Time to ≥ 1-point improvement (days) from baseline clinical status [Day 1 to Day 28]
- Time to recovery: defined as an improvement in clinical status from a baseline score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7 [Day 1 to Day 28]
- Duration of oxygen therapy (days) [Day 1 to Day 28]
- Proportion of patients with shift in oxygen support status from baseline [Day 1 to Day 28]
- Duration of hospitalization (days) [Day 1 to Day 28]
- Number of patients with all-cause mortality at Day 28 [Day 1 to Day 28]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
SARS-Co-V2 positivity to the nasal-swab by reverse-transcriptase-polymerase chain- reaction (RT-PCR) assay tested by the local diagnostic laboratory
-
Age >18 years
-
Presence of any symptoms suggestive of COVID-19, such as such as fever, fatigue, cough (with or without sputum production), shortness of breath, sore throat, nasal congestion, anorexia, malaise, or headache. Rarely, patients may also present with diarrhea, nausea, and vomiting
-
Presence of radiological findings of pneumonia assessed by chest radiograph, computed tomography
-
Moderate and severe COVID-19 as per previous definition national guideline/WHO
-
Give informed written consent
Exclusion Criteria:
-
Absolute lymphocyte count <500/mm3 and absolute neutrophil count of <1000/mm3 and Hemoglobin 8gm/dl or less
-
Severe hepatic or renal impairment
-
Live vaccine within 3 months prior to first dose of the drug
-
Pregnancy
-
Lactation
-
Current malignancy or history of malignancies over the previous 5 years and/or history of malignancies in first degree relatives
-
Transaminases values 5-fold higher than the upper normal limit
-
Proven evidence of concomitant bacterial infections
-
Clinical evidences suggestive of pulmonary tuberculosis, or past history and/or history of contact with TB patient
-
Known hypersensitivity to Baricitinib
-
Those who have received Tocilizumab previously
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Dhaka Medical College, Mugda Medical College, Kuwait Bangladesh Friendship Government Hospital | Dhaka | Bangladesh |
Sponsors and Collaborators
- Incepta Pharmaceuticals Ltd
Investigators
- Principal Investigator: Md. Titu Miah, MBBS, FCPS, Dhaka Medical College
- Principal Investigator: Md. Mujibur Rahman, MBBS, MD, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021/BR8/P3/01